Results 291 to 300 of about 170,525 (342)

Non-alcoholic steatohepatitis incidence in patients with psoriasis vulgaris. [PDF]

Wien Med Wochenschr
Elhanon HM, Atallah RB, Eldahshan RM, Mohamed SED, Elsaie ML.   +4 more
europepmc   +1 more source

M1992 Usefulness of Serum High-Sensitivity CRP Measurement in Differentiating Between Non-Alcoholic Steatohepatitis and Simple Steatosis in Patients With Non-Alcoholic Fatty Liver Disease

, 2010
Sith Siramolpiwat, C Pramoolsinsap, Naruemon Wisedopas   +2 more
openalex   +1 more source

Effect of interdisciplinary obesity care on metabolic markers and body weight in people with type 2 diabetes in a rural setting: A randomised controlled trial

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Management of type 2 diabetes includes medications that can unintentionally increase obesity and insulin resistance. This unblinded, single‐centre, randomised controlled trial focused on rural Australian adults with type 2 diabetes (aged 18–75 and body mass index [BMI] >30 kg/m2), measuring the effectiveness of a tailored interdisciplinary ...
Giuliana O. Murfet, Iain K. Robertson, Sharon P. Luccisano, Michelle L. Kilpatrick   +3 more
wiley   +1 more source

Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: A systematic review. [PDF]

World J Gastrointest Pharmacol Ther
Kamrul-Hasan ABM, Borozan S, Jena S, Nagendra L, Dutta D, Bhattacharya S, Islam MS, Pappachan JM.   +7 more
europepmc   +1 more source

Beyond BMI: Practical Guide for Clinicians to Integrate the Lancet Commission's Obesity Framework and King's Obesity Staging System

Clinical Obesity, EarlyView.
ABSTRACT Body mass index (BMI) on its own is a poor diagnostic and staging tool for obesity because it does not measure health status. The newly published Lancet Clinical Obesity Criteria (LCOC) for defining clinical obesity distinguish preclinical and clinical obesity based on organ or tissue dysfunction.
Tak Ying Louise Ko, Alexander D. Miras, Dimitri J. Pournaras, Carel W. Le Roux   +3 more
wiley   +1 more source

Co-treatment of trigonelline and everolimus synergistically prevented chronic steatohepatitis induced by fast food diet and thioacetamide in a novel murine nonalcoholic steatohepatitis model.

Indian J Pharmacol
Sharma RR, Sharma L, Rashid H, Bhat AM, Gupta D, Tasduq SA.   +5 more
europepmc   +1 more source

A comparison of trends in the incidence of non-alcoholic steatohepatitis-related liver cancer in the BRICS countries from 1990 to 2021, alongside projections for the next 15 years. [PDF]

Front Oncol
Chen C, Huang S, Wu H, Hu W, Li C, Du D, Fang T.   +6 more
europepmc   +1 more source

Development of NAFLD‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation

Cell Proliferation, EarlyView.
Microporous array organ chips were integrated with commercially available well plates to develop organoid chip platforms, which enable modelling of hepatic physiology and non‐alcoholic fatty liver disease (NAFLD) pathogenesis, as well as evaluation of semaglutide therapeutics. ABSTRACT Progressive non‐alcoholic fatty liver disease (NAFLD) may culminate
Xiao‐yan You, Xiang‐yang Li, Hui Wang, Guo‐ping Zhao   +3 more
wiley   +1 more source

The Construction and Performance Evaluation of a Risk Prediction Model for Nonalcoholic Steatohepatitis Based on Serological Markers. [PDF]

Gastroenterol Res Pract
Huang D, Zhang W, Fang Y, Liu T, Zhou D.
europepmc   +1 more source

Vitronectin deficiency attenuates hepatic fibrosis in a non‐alcoholic steatohepatitis‐induced mouse model

, 2019
Momoka Hayashida, Kei Hashimoto, Tomoko Ishikawa, Yasunori Miyamoto   +3 more
openalex   +2 more sources